Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
-
Patent number: 8735364Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.Type: GrantFiled: January 3, 2008Date of Patent: May 27, 2014Assignee: Genzyme CorporationInventors: Rosanne M. Crooke, Mark J. Graham
-
Patent number: 8735365Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.Type: GrantFiled: January 13, 2011Date of Patent: May 27, 2014Assignee: Phigenix, Inc.Inventor: Carlton D. Donald
-
Patent number: 8735159Abstract: The present invention relates to the use of nucleic acid sequences for regulating the transcription and expression of genes, the novel promoters and expression units themselves, methods for altering or causing the transcription rate and/or expression rate of genes, expression cassettes comprising the expression units, genetically modified microorganisms with altered or caused transcription rate and/or expression rate, and methods for preparing biosynthetic products by cultivating the genetically modified microorganisms.Type: GrantFiled: March 17, 2008Date of Patent: May 27, 2014Assignee: BASF SEInventors: Oskar Zelder, Corinna Klopprogge, Burkhard Kroger, Hartwig Schroder, Stefan Haefner
-
Patent number: 8735562Abstract: The present invention encompasses isolated gene regulatory elements and gene transcription terminators that are differentially expressed in a native fungus exhibiting a first morphology relative to the native fungus exhibiting a second morphology. The invention also encompasses a method of utilizing a fungus for protein or chemical production. A transformed fungus is produced by transforming a fungus with a recombinant polynucleotide molecule. The recombinant polynucleotide molecule contains an isolated polynucleotide sequence linked operably to another molecule comprising a coding region of a gene of interest. The gene regulatory element and gene transcription terminator may temporally and spatially regulate expression of particular genes for optimum production of compounds of interest in a transgenic fungus.Type: GrantFiled: October 23, 2008Date of Patent: May 27, 2014Assignee: Battelle Memorial InstituteInventors: Ziyu Dai, Linda L. Lasure, Jon K. Magnuson
-
Publication number: 20140141517Abstract: Isolated polynucleotides comprising a PCP2 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.Type: ApplicationFiled: November 21, 2013Publication date: May 22, 2014Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra, Charles de Leeuw
-
Patent number: 8729339Abstract: The invention provides methods and compositions useful in target sequence suppression and target sequence validation. The invention provides polynucleotide constructs useful for gene silencing, as well as cells, plants and seeds comprising the polynucleotides. The invention also provides a method for using microRNA to silence a target sequence.Type: GrantFiled: December 18, 2007Date of Patent: May 20, 2014Assignee: E.I du Pont de Nemours and CompanyInventor: Milo J. Aukerman
-
Patent number: 8728760Abstract: The present invention relates generally to stabilized expression plasmid systems. The stabilized expression plasmid systems comprise an expression vector that includes a plasmid maintenance system (PMS) and, optionally, one or both of a polynucleotide encoding a selected antigen under control of a promoter, and a polynucleotide encoding a selectable marker under control of a promoter. The use of the mchI protein as a selectable marker is found in preferred embodiments of the invention.Type: GrantFiled: April 3, 2008Date of Patent: May 20, 2014Assignee: University of Maryland, BaltimoreInventors: James E. Galen, Chee-Mun Fang
-
Patent number: 8729041Abstract: The present invention provides compositions and methods featuring miR-26 microRNA polynucleotides for the diagnosis, treatment or prevention of hepatic neoplasia.Type: GrantFiled: December 2, 2009Date of Patent: May 20, 2014Assignees: The Johns Hopkins University, Nationwide Children's Hospital, Inc.Inventors: Joshua T. Mendell, Kathryn A. Mendell, Raghu R. Chivukula, Erik A. Wentzel, Jerry R. Mendell, K. Reed Clark, Janaiah Kota
-
Patent number: 8729340Abstract: The present invention relates to a Solanum lycopersicum histidine decarboxylase-2 (SlHD-2) gene-derived fruit-specific expression promoter, to a 5? untranslated region (5?-UTR), to a (5?UTR), —specific expression vector comprising same, to a method for the fruit-specific expression of an exotic gene using the expression vector, to a plant transformed with the expression vector, and to a seed thereof. According to the present invention, a gene introduced from a transformed plant can be specifically expressed fruit tissue as compared to the widely used conventional Cauliflower mosaic virus-derived CaMV 35S promoter which induces the expression of an exotic gene in the whole tissue. Further, the present invention can be valuably used in the development of a transformed plant, which seeks to produce valuable substances from fruit.Type: GrantFiled: February 11, 2010Date of Patent: May 20, 2014Assignee: Industry Foundation of Chonnam National UniversityInventors: Young Hee Joung, Ah Young Kim, Sang Hyeob Lee
-
Patent number: 8722642Abstract: A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.Type: GrantFiled: March 18, 2013Date of Patent: May 13, 2014Assignee: Biocell LaboratoriesInventor: Zenoviy Tkachuk
-
Patent number: 8722867Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.Type: GrantFiled: March 26, 2011Date of Patent: May 13, 2014Assignee: Tocagen Inc.Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
-
Patent number: 8722640Abstract: The present invention is based, at least in part, on novel, unimolecular STAT3 oligonucleotide decoys exhibiting increased in vivo stability as compared to previously known decoys which are effective in inhibiting STAT3 when administered systemically. The invention is also based on pharmaceutical compositions comprising these unimolecular decoys, and methods for using these decoys in the treatment of cancer.Type: GrantFiled: June 7, 2012Date of Patent: May 13, 2014Inventors: Jennifer R. Grandis, Daniel Johnson, Danith Ly
-
Patent number: 8722873Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.Type: GrantFiled: February 22, 2010Date of Patent: May 13, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Susan M. Freier, James G. Karras
-
Publication number: 20140127265Abstract: The present disclosure provides an isolated or purified guinea pig cytomegalovirus (GPCMV) Strain CIDMTR, glycoproteins from GPCMV Strain CIDMTR, and methods of use thereof.Type: ApplicationFiled: October 21, 2013Publication date: May 8, 2014Inventor: MARK SCHLEISS
-
Patent number: 8716255Abstract: The invention provides methods, uses, kits and compositions comprising a therapeutically effective amount of the microRNA miR-223 for treating myelogenous leukemia in a subject in need of such treatment. The invention further comprises methods encompassing the use of miR-223 for promoting the differentiation of a leukemia stem cell that is resistant to a differentiating agent, and a method of screening for candidate compounds capable of treating a myeloid leukemia by comparison of the therapeutic activity of the candidate compound with the therapeutic activity of miR-233.Type: GrantFiled: August 11, 2008Date of Patent: May 6, 2014Assignee: British Columbia Cancer Agency BranchInventors: Florian Kuchenbauer, Michael Heuser, Richard Keith Humphries
-
Patent number: 8716021Abstract: Regulatory elements, specifically replicators and transgene constructs containing replicator nucleic acid sequences, are disclosed herein. Methods of using replicators and transgene constructs including replicators to inhibit, delay, or prevent gene silencing are also disclosed herein.Type: GrantFiled: September 7, 2006Date of Patent: May 6, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Mirit I. Aladjem, Cindy Tseng, Haiqing Fu, Lixin Wang
-
Patent number: 8715968Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).Type: GrantFiled: December 23, 2003Date of Patent: May 6, 2014Assignee: Xenon Pharmaceuticals Inc.Inventors: Michael R. Hayden, Angela R. Brooks-Wiison, Simon N. Pimstone
-
Patent number: 8716256Abstract: There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.Type: GrantFiled: June 3, 2011Date of Patent: May 6, 2014Assignee: Kaoshiung Medical UniversityInventors: Suh-Hang Juo, Ku-Chung Chen, I-Chung Hsieh, Ching-Yu Hu
-
Patent number: 8716463Abstract: Nucleic acid molecules which encode a branching enzyme from a bacterium of the genus Neisseria, vectors, host cell, plant cells and plants containing said nucleic acid molecules as well as starch obtainable from the plants described are described. Furthermore, an in-vitro method for producing ?-1,6-branched ?-1,4-glucans on the basis of sucrose and a combination of enzymes of an amylosucrase and a branching enzyme as well as the ?-1,6-branched ?-1,4-glucans obtainable by said method are described.Type: GrantFiled: July 29, 2011Date of Patent: May 6, 2014Assignee: Bayer Bioscience GmbHInventors: Volker Büttcher, Martin Quanz
-
Patent number: 8715927Abstract: Disclosed herein is the identification of human DNA polymerase ? (pol ?) as the polymerase that mediates repair of DNA containing interstrand cros slinks (ICLs). The mechanism of action of a number of chemotherapeutic and antimicrobial agents is the induction of ICLs. Thus, provided herein is a method of enhancing the efficacy of a chemotherapeutic or antimicrobial agent in a subject, including selecting a subject in need of treatment with an ICL -inducing agent and administering to the subject an ICL-inducing agent and a therapeutically effective amount of an inhibitor of pol ?. Also provided is a composition for treating a hyperproliferative disease, an autoimmune disease or an infectious disease, comprising an ICL-inducing agent and an amount of an inhibitor of pol ? sufficient to enhance the efficacy of the ICL-inducing agent. Further provided is a method of identifying a DNA polymerase inhibitor.Type: GrantFiled: April 22, 2009Date of Patent: May 6, 2014Assignee: Oregon Health & Science UniversityInventors: R. Stephen Lloyd, Irina G. Minko, Amanda K. McCullough
-
Patent number: 8716464Abstract: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and methods of use thereof, e.g., for preventing or treating EBOV infections caused by one or more EBOV species such as Zaire EBOV. The invention also provides serum-stable nucleic acid-lipid particles comprising one or more interfering RNA molecules, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles. Methods of silencing EBOV gene expression by administering one or more interfering RNA molecules to a mammalian subject are also provided.Type: GrantFiled: July 20, 2010Date of Patent: May 6, 2014Inventors: Thomas W. Geisbert, Amy C. H. Lee, Marjorie Robbins, Vandana Sood, Adam Judge, Lisa E. Hensley, Ian MacLachlan
-
Patent number: 8716462Abstract: The invention encompasses methods for improving the level and/or sustainability of expression for a target nucleic acid in a eukaryotic cell comprising: (a) modifying the target nucleic acid to introduce or to comprise signals that limit or constrain the positions of nucleosome cores, and (b) introducing the modified target nucleic acid into the eukaryotic cell, wherein the modified target nucleic acid has improved levels and/or sustainability of expression compared to original unmodified nucleic acid.Type: GrantFiled: January 29, 2007Date of Patent: May 6, 2014Assignees: Carnegie Institution of Washington, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Andrew Fire, Lia Gracey, Weng-Onn Lui
-
Patent number: 8716555Abstract: The present specification relates to the production of cotton plants and seeds and oil prepared therefrom having elevated levels of oleic and reduced levels of palmitic and linoleic acids. Furthermore, cottonseeds having low levels of cyclopropane and/or cyclopropene fatty acids and/or reduced levels of gossypol are described herein. The specification also describe FatB and CPA-FAS nucleotide and amino acid sequences derived from cotton facilitating, inter alia the direct modification of plant oil content and/or composition.Type: GrantFiled: January 21, 2011Date of Patent: May 6, 2014Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Qing Liu, Allan Graham Green, Surinder Pal Singh
-
Publication number: 20140123345Abstract: The invention found that partial deletion of the glyceraldehyde-3-phosphate dehydrogenase (gpd) promoter can enhance gene expression (even heterologous gene expression) in basidiomycetous fungi. With the discovery of these gpd promoters, an expression system can be constructed for the expression of a heterologous gene in mushroom. Accordingly, the invention provides a truncated glyceraldehyde-3-phosphate dehydrogenase promoter and a construct comprising the promoter of the invention operably linked to a heterologous transcribable polynucleotide molecule and a mushroom comprising the construct.Type: ApplicationFiled: October 26, 2012Publication date: May 1, 2014Applicant: MYCOMAGIC BIOTECHNOLOGY CO., LTD.Inventor: Ying-Tzu Lyu
-
Publication number: 20140121364Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.Type: ApplicationFiled: December 30, 2013Publication date: May 1, 2014Applicant: REGULUS THERAPEUTICS INC.Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
-
Patent number: 8710205Abstract: The present invention relates to a transcription factor found in filamentous fungi, especially in Aspergillii, DNA sequences coding for said factor, its transformation into and expression in fungal host organisms, and the use of said factor in such hosts for increasing the expression of a polypeptide of interest being produced by said host.Type: GrantFiled: February 20, 2003Date of Patent: April 29, 2014Assignee: Novozymes A/SInventor: Tove Christensen
-
Patent number: 8710021Abstract: The present invention refers to agents for modulating the activity of proteins having a PWWP domain.Type: GrantFiled: June 10, 2009Date of Patent: April 29, 2014Assignee: Bionucleon S.r.l.Inventors: Valentina Anro, Sarah Dewilde, Domenico Barone, Nicoletta Minari, Enrico M. Bucci, Roberto Sapio, Margherita Valente, Sara Tosti, Laura Ricci
-
Patent number: 8710297Abstract: A glycosyltransferase promoter and a recombinant nucleic acid, plant cell and transgenic plant containing thereof are provided. The promoter includes a nucleotide sequence as set forth in any one of SEQ ID NOs: 1˜7, a fragment having at least 10 contiguous bases of any one of SEQ ID NOs: 1˜7 or a combination thereof, or a nucleotide sequence having 90% or more identity to the nucleotide sequence as set forth in any one of SEQ ID NOs: 1˜7.Type: GrantFiled: July 21, 2011Date of Patent: April 29, 2014Assignee: Industrial Technology Research InstituteInventors: Shu-Jiau Chiou, Cheng-Yu Lee, Pei-Hsuan Wei, Jui-Hung Yen, Cheng-Li Fang
-
Patent number: 8709811Abstract: The subject invention concerns polynucleotides encoding a plant 2-phenylethanol dehydrogenase enzyme. In one embodiment, the polynucleotide encodes a tomato 2-phenylethanol dehydrogenase. The subject invention also concerns polynucleotides encoding a plant phenylalanine decarboxylase enzyme. In one embodiment, the polynucleotide encodes a tomato phenylalanine decarboxylase. The subject invention also concerns 2-phenylethanol dehydrogenase polypeptides and phenylalanine decarboxylase polypeptides encoded by polynucleotides of the present invention. The subject invention also concerns methods for providing a plant with an increased flavor and aroma volatile. Plants can be transformed with one or more polynucleotide of the present invention. The subject invention also concerns these transformed plant cells, plant tissue, and plants and transgenic progeny thereof.Type: GrantFiled: October 1, 2004Date of Patent: April 29, 2014Assignee: University of Florida Research Foundation, Inc.Inventors: Harry J. Klee, Denise Tieman
-
Patent number: 8709754Abstract: The embodiments of the present invention are directed to discrete, cis-acting regulatory elements that include a barrier element, an insulating element, a silencing element, and matrix attachment regions (“MARs”). Additional embodiments of the present invention are directed to nucleic acid molecules that are useful for facilitating stable transgene expression within a chromatin environment. Additional embodiments of the present invention are directed to recombinant expression vectors including nucleic acid molecules of the present invention that can be incorporated into artificial chromosomes, eukaryotic cell-lines, non-human transgenic animals, and transgenic plants, to improve recombinant protein production in a broad range of eukaryotic hosts, and pharmaceutical compositions including nucleic acid molecules of the present invention that are also useful for gene therapy in the treatment of various genetic diseases.Type: GrantFiled: July 17, 2007Date of Patent: April 29, 2014Assignee: University of WashingtonInventors: Anton Krumm, Wendy Gombert
-
Patent number: 8709766Abstract: The present disclosure is directed to novel polynucleotide sequences for use in Nannochloropsis gaditana. The novel polynucleotide sequences include control sequences and coding sequences. Also disclosed are novel gene expression constructs wherein N. gaditana promoters/control regions are operatively linked to N. gaditana or non-N. gaditana coding sequences. These novel polynucleotide sequences and expression constructs can be introduced into N. gaditana and can recombine into the N. gaditana genome. Expression from these polynucleotide sequences and expression constructs can enhance N. gaditana biomass and/or lipid biosynthesis. Also disclosed are methods for modifying N. gaditana, for example by stably transforming N. gaditana with nucleic acid sequences, growing the modified N. gaditana, and obtaining biomass and biofuels from the modified N. gaditana.Type: GrantFiled: October 17, 2012Date of Patent: April 29, 2014Assignee: Colorado School of MinesInventors: Randor Radakovits, Robert Jinkerson, Matthew Posewitz
-
Patent number: 8710207Abstract: The present disclosure relates, in some embodiments, to compositions, organisms, systems, and methods for expressing a gene product in a plant using a expression control sequence (ECS) operable in monocots and/or dicots. For example, (i) an isolated nucleic acid may comprise an ECS (e.g., a sugarcane bacilliform virus promoter) and, optionally, an exogenous nucleic acid (ExNA) operably linked to the ECS; (ii) an expression vector may comprise an ECS; an ExNA; and, optionally, a 3? termination sequence, wherein the ECS has promoter activity sufficient to express the ExNA in at least one monocot and at least one dicot; (iii) a microorganism, plant cell, or plant may comprise an isolated nucleic acid; (iv) a method for constitutively expressing an ExNA in a plant (e.g.Type: GrantFiled: May 10, 2011Date of Patent: April 29, 2014Assignee: The Texas A&M University SystemsInventors: T. Erik Mirkov, Jong Won Park, San-Ji Gao
-
Patent number: 8710206Abstract: The promoter of a soybean translation elongation factor EF1 alpha, a polypeptide that promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis, and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in a tissue-independent or constitutive manner in plants are described.Type: GrantFiled: May 14, 2008Date of Patent: April 29, 2014Assignee: E. I. du Pont de Nemours and CompanyInventor: Zhongsen Li
-
Patent number: 8710209Abstract: Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.Type: GrantFiled: December 8, 2010Date of Patent: April 29, 2014Assignee: Nitto Denko CorporationInventors: Xiaomei Jin, Lei Yu, Hirokazu Takahashi, Yasunobu Tanaka, Yoshiro Niitsu, Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett, Shai Erlich, Elizabeth C. Squiers, Ning Chen
-
Patent number: 8710023Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of C-reactive protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding C-reactive protein. Methods of using these compounds for modulation of C-reactive protein expression and for treatment of diseases associated with expression of C-reactive protein are provided.Type: GrantFiled: December 2, 2011Date of Patent: April 29, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Rosanne M. Crooke, Mark J. Graham
-
Patent number: 8709813Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.Type: GrantFiled: July 17, 2012Date of Patent: April 29, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Dennis J Kopecko, Chandrakant P Giri
-
Publication number: 20140113368Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.Type: ApplicationFiled: December 4, 2013Publication date: April 24, 2014Applicant: Bavarian Nordic A/SInventors: Jürgen HAUSMANN, Karen Baur, Kay Brinkmann
-
Patent number: 8704041Abstract: A variety of methods and compostions are provided, including methods and compositions for targeted modification of a specific target site in a cell or organism, methods for integrating polynucleotides of interest, methods to assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excise a polynucleotide, silence a gene, and identify and/or characterize transcriptional regulating regions. The methods involve the introduction of a cell proliferation factor and a double-strand break-inducing enzyme into an organism.Type: GrantFiled: December 30, 2010Date of Patent: April 22, 2014Assignee: Pioneer Hi Bred International IncInventors: William J. Gordon-Kamm, Keith S. Lowe, David J. Peterson, Christopher J. Scelonge, Grace M. St. Clair, Bing-Bing Wang
-
Patent number: 8703730Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.Type: GrantFiled: July 10, 2009Date of Patent: April 22, 2014Assignee: Regenesance B.V.Inventors: Frank Baas, Kees Fluiter
-
Publication number: 20140107187Abstract: The present invention provides (a) a functional nucleic acid molecule comprises: a target determinant sequence comprising antisense sequence to a target sequence in the protein-encoding RNA for which protein synthesis efficiency is to be increased and a regulatory sequence having an activity of increasing of the protein synthesis efficiency, and (b) a use of the functional nucleic acid molecule.Type: ApplicationFiled: March 30, 2012Publication date: April 17, 2014Applicants: INTERNATIONAL SCHOOL FOR ADVANCED STUDIES, RIKENInventors: Piero Carninci, Alistair Forrest, Stefano Gustincich, Claudia Carrieri, Silvia Zucchelli
-
Patent number: 8697440Abstract: The present invention relates to methods and tools for producing large quantities of gamma-carboxylated protein comprising: (i) culturing a cell adapted to express a protein which requires gamma-carboxylation and ?-glutamyl carboxylase in a ratio of at least 10:1, under conditions suitable for expression of both proteins, and (ii) isolating gamma-carboxylated protein.Type: GrantFiled: November 19, 2010Date of Patent: April 15, 2014Assignee: Medimmune LimitedInventors: Christel Fenge, Ann Lövgren, Anders Thelin
-
Patent number: 8697359Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.Type: GrantFiled: October 15, 2013Date of Patent: April 15, 2014Assignees: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventor: Feng Zhang
-
Patent number: 8697087Abstract: Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator.Type: GrantFiled: November 6, 2006Date of Patent: April 15, 2014Assignee: Novartis AGInventors: Rino Rappuoli, Derek O'Hagan, Giuseppe Del Giudice
-
Patent number: 8697858Abstract: The present invention relates to antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal.Type: GrantFiled: November 12, 2010Date of Patent: April 15, 2014Assignee: Sarepta Therapeutics, Inc.Inventor: Patrick L. Iversen
-
Patent number: 8697857Abstract: The promoter of a soybean translation elongation factor EF1 alpha, a polypeptide that promotes the GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis, and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in a tissue-independent or constitutive manner in plants are described.Type: GrantFiled: November 20, 2008Date of Patent: April 15, 2014Assignee: E. I. du Pont de Nemours and CompanyInventor: Zhongsen Li
-
Patent number: 8697949Abstract: This invention provides molecular constructs and methods for the temporally specific control of gene expression in plants or in plant pests or pathogens. More specifically, this invention provides plant miRNA genes having novel circadian expression patterns that are useful for designing recombinant DNA constructs for temporally specific expression of at least one gene. Also provided are non-natural transgenic plant cells, plants, and seeds containing in their genome a recombinant DNA construct of this invention.Type: GrantFiled: June 26, 2008Date of Patent: April 15, 2014Assignee: Monsanto Technology LLCInventors: Edwards Allen, Sara E. Heisel, Sergey Ivashuta, Elysia Krieger, Jennifer Lutke, Robert J. Meister, Yuanji Zhang
-
Patent number: 8697947Abstract: The present invention relates generally to the field of molecular biology and concerns a method for increasing various plant yield-related traits by modulating expression in a plant of a nucleic acid sequence encoding a yield increasing polypeptide selected from the group consisting of: an AT-hook motif nuclear localized 19/20 (AHL19/20), a GRP (Growth Regulating Protein) (wherein said GRP polypeptide is a metallothionein 2a (MT2a) polypeptide), an alanine aminotransferase (AAT)-like polypeptide, and an alanine aminotransferase (AAT) polypeptide.Type: GrantFiled: July 21, 2008Date of Patent: April 15, 2014Assignee: BASF Plant Science GmbHInventors: Yves Hatzfeld, Valerie Frankard
-
Publication number: 20140099669Abstract: The present invention relates to methods for producing a biological substance, comprising: (a) cultivating a fungal host cell in a medium conducive for the production of the biological substance, wherein the fungal host cell comprises a first nucleic acid sequence encoding the biological substance operably linked to a second nucleic acid sequence comprising a promoter variant selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12; and a subsequence thereof; and hybrid and tandem promoters thereof; and (b) isolating the biological substance from the cultivation medium. The present invention also relates to the isolated promoter variants and to constructs, vectors, and fungal host cells comprising the promoter variants operably linked to nucleic acid sequences encoding biological substances.Type: ApplicationFiled: December 5, 2013Publication date: April 10, 2014Inventors: Debbie Yaver, Peter Nham
-
Publication number: 20140099284Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.Type: ApplicationFiled: October 14, 2011Publication date: April 10, 2014Applicant: EOS NEUROSCIENCE, INCInventors: Alan Horsager, Andrew Smith, Benjamin C. Matteo
-
Patent number: 8691962Abstract: The invention provides isolated plant gene promoters and regulatory elements that are root specific and/or induced by plant parasitic nematodes. The promoters of the invention are useful for controlling expression of nucleic acids of interest in plant roots and are particularly useful for controlling transcription of nucleic acids encoding agents that disrupt formation or maintenance of parasitic nematode feeding sites in plants.Type: GrantFiled: December 20, 2007Date of Patent: April 8, 2014Assignee: BASF Plant Science GmbHInventors: Aaron Wiig, Robert Ascenzi, Xiang Huang, Sumita Chaudhuri, Rui-Guang Zhen, Yu Han